Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vidaza

- PMLiVE

Celgene lifted by apremilast data in psoriatic arthritis

Long-term data keeps marketing application plans on course

- PMLiVE

Celgene’s Revlimid knocked-back by NICE

Final draft guidance from NICE does not recommend drug for rare bone marrow disorder

- PMLiVE

Celgene wins US pancreatic cancer indication for Abraxane

Adds to breast cancer and lung cancer indications

EU flag

Europe backs two blood cancer treatments

Approvals for J&J’s Velcade and Celgene’s Imnovid for treatment of multiple myeloma

- PMLiVE

Celgene halts Revlimid trial after patient deaths

High mortality rate in trial involving elderly patients with rare leukaemia

- PMLiVE

Revlimid faces NICE rejection for use in rare blood cancer

Watchdog's draft guidance does not recommend Celgene's drug for NHS use in England and Wales

- PMLiVE

Celgene wins expanded EU approval for cancer drug Revlimid

Approved for use in patients with rare blood disorder

- PMLiVE

Celgene’s Revlimid wins US lymphoma approval

FDA recommends extra indication for blockbuster cancer drug

- PMLiVE

EMA backs Pomalidomide Celgene in multiple myeloma

Further positive CHMP opinions for new medicines form Aegerion, Teva and more

- PMLiVE

Celgene promotes Karen Browne to haematology director

She takes up a new role with the company's UK and Ireland business

- PMLiVE

Celgene’s apremilast set for 2013 filing

Pharma company releases positive phase III results for psoriasis candidate

- PMLiVE

Celgene gets US green light for blockbuster candidate Pomalyst

FDA approval to treat multiple myeloma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links